drugset / Trial / NCT00220324

Pearl Index Study With Low Dose Combined Oral Contraceptive

NCT00220324

Phase 3 Completed 840 enrolled Bayer
Non-randomizedSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to investigate the contraceptive efficacy, bleeding pattern, and safety of SH D00342A. Subjects participating in the study will be treated with an oral contraceptive pill containing 0.03 mg ethinylestradiol and 0.125 mg levonorgestrel.

Timeline

Start
2004-02
Primary completion
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Levonorgestrel Small molecule 0.125 mg Oral
Subject ethinyl estradiol Small molecule 0.03 mg Oral

Indications

No indication recorded.